SCF\(^{β-TRCP}\) Suppresses Angiogenesis and Thyroid Cancer Cell Migration by Promoting Ubiquitination and Destruction of VEGF Receptor 2
DSpace/Manakin Repository
SCF\(^{β-TRCP}\) Suppresses Angiogenesis and Thyroid Cancer Cell Migration by Promoting Ubiquitination and Destruction of VEGF Receptor 2
| Title: | SCF\(^{β-TRCP}\) Suppresses Angiogenesis and Thyroid Cancer Cell Migration by Promoting Ubiquitination and Destruction of VEGF Receptor 2 |
| Author: |
Shaik, Shavali; Nucera, Carmelo; Inuzuka, Hiroyuki; Gao, Daming; Garnaas, Maija; Frechette, Gregory Martin; Harris, Lauren; Wan, Lixin; Fukushima, Hidefumi; Husain, Amjad; Nose, Vania; Fadda, Guido; Sadow, Peter Mark; Goessling, Wolfram; North, Trista Elizabeth; Lawler, Jack William; Wei, Wenyi
Note: Order does not necessarily reflect citation order of authors. |
| Citation: | Shaik, Shavali, Carmelo Nucera, Hiroyuki Inuzuka, Daming Gao, Maija Garnaas, Gregory Frechette, Lauren Harris, et al. 2012. SCF\(^{β-TRCP}\) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. The Journal of Experimental Medicine 209(7): 1289-1307. |
| Full Text & Related Files: |
3405505.pdf (4.676Mb; PDF) 
|
| Abstract: | The incidence of human papillary thyroid cancer (PTC) is increasing and an aggressive subtype of this disease is resistant to treatment with vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor. VEGFR2 promotes angiogenesis by triggering endothelial cell proliferation and migration. However, the molecular mechanisms governing VEGFR2 stability in vivo remain unknown. Additionally, whether VEGFR2 influences PTC cell migration is not clear. We show that the ubiquitin E3 ligase SCF\(^{β-TRCP}\) promotes ubiquitination and destruction of VEGFR2 in a casein kinase I (CKI)–dependent manner. β-TRCP knockdown or CKI inhibition causes accumulation of VEGFR2, resulting in increased activity of signaling pathways downstream of VEGFR2. β-TRCP–depleted endothelial cells exhibit enhanced migration and angiogenesis in vitro. Furthermore, β-TRCP knockdown increased angiogenesis and vessel branching in zebrafish. Importantly, we found an inverse correlation between β-TRCP protein levels and angiogenesis in PTC. We also show that β-TRCP inhibits cell migration and decreases sensitivity to the VEGFR2 inhibitor sorafenib in poorly differentiated PTC cells. These results provide a new biomarker that may aid a rational use of tyrosine kinase inhibitors to treat refractory PTC. |
| Published Version: | doi:10.1084/jem.20112446 |
| Other Sources: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405505/pdf/ |
| Terms of Use: | This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
| Citable link to this page: | http://nrs.harvard.edu/urn-3:HUL.InstRepos:10611735 |
| Downloads of this work: |
This item appears in the following Collection(s)
-
HMS Scholarly Articles [20072]
Contact administrator regarding this item (to report mistakes or request changes)
